Recently, the State Food and Drug Administration approved the first domestic bivalent human papillomavirus vaccine (E. coli) (trade name: 馨可宁) for the marketing registration application.
is priced at 329 yuan per tube and is suitable for women aged 9-45.
This product is jointly developed by the team of Xiamen University Xia Ningshao and Xiamen Wantai. It is the first approved domestic human papillomavirus vaccine, suitable for 9-45 years old female.
According to Xiamen Wantai news, Xinkening is priced at 329 yuan per tube. Women aged 9-14 only need 2 injections, and women aged 15-45 are vaccinated with 3 injections. The product is currently being put into production.
Following the United States and Britain, China has successfully developed the HPV vaccine
HPV vaccine is the abbreviation of cervical cancer vaccine, mainly used to prevent cervical cancer in women. Studies have found that 99.7% of cervical cancers are caused by infection with human papillomavirus (HPV). There are currently more than 100 known types of HPV viruses, of which at least 14 genotypes (ie, high-risk types) are considered to cause cervix cancer.
△Data map
According to the types of virus subtypes covered by the vaccine, cervical cancer vaccines can be divided into divalent, quadrivalent and ninth-valent. The bivalent HPV vaccine has a protective effect on two high-risk types (HPV-16 and HPV-18), and 84.5% of cervical cancers in the Chinese population are caused by these two. The quadrivalent HPV vaccine adds two low-risk types HPV-6 and HPV-11 on the basis of the bivalent HPV vaccine, which can reduce the occurrence of condyloma acuminatum. The nine-valent HPV vaccine adds 5 high-risk types on the basis of the quadrivalent. Type. The listing of
Xinkening also means that China has thus become the third country in the world to successfully develop and produce HPV vaccines after the United States and Britain. The HPV vaccine market previously monopolized by foreign pharmaceutical companies finally ushered in local players.
△Data chart
There is a gap of 1 billion in the HPV vaccine market.
Since the first HPV vaccine was launched in 2006, the current cumulative sales of HPV vaccines are about 350 million, and the annual demand is 100 million, and the demand is increasing. According to data from the China Institute for Food and Drug Control, the number of HPV vaccines issued in my country was 1.46 million in 2017, 7 million in 2018, and 8.7 million in January-November 2019. is calculated on the basis of 356 million women of the right age and 3 needles per person, the market gap exceeds 1 billion.
is in a community vaccination hospital in Putuo District, Shanghai. The price of the nine-valent HPV vaccine is about 1300 yuan per shot, the price of the quadrivalent HPV vaccine is about 800 yuan per shot, and the bivalent HPV vaccine is about 600 yuan per shot. They are about 4000 yuan, 2400 yuan and 1800 yuan respectively.
Faced with several products that are already on the market in China and have first-mover advantages, the price of Cinkening 329 yuan per tube is priced at 660 yuan for 2 injections, and about 1,000 yuan for 3 injections, provided that the protection rate is not much different. , More price advantage.
▌ Source of this article: CCTV News Comprehensive Economic Observation Network
